Biotech News

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma (LYEL)Lyell Immunopharma2026-03-12 20:05 ESTEarnings

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoing Phase 1 trial is ongoing for LYL273, an enhanced

Open original release

Related news

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

FATEFate Therapeutics2026-05-13 12:30 EST

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

IMTXImmatics2026-05-12 11:00 EST

Immatics Announces First Quarter 2026 Financial Results and Business Update

BMEABiomea Fusion2026-05-11 20:55 EST

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

RVMDRevolution Medicines2026-05-06 20:02 EST

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

BNTXBioNTech2026-07-21 10:45 EST

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

View all latest news

Lyell Immunopharma

Lyell Immunopharma is a cell-therapy company focused on reprogramming T cells for durable cancer treatment. Its work centers on improving persistence and potency in cellular immunotherapy.

Recent company news

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

LYELLyell Immunopharma2026-05-12 12:00 EST

Lyell Immunopharma Announces Participation in May Investor Conferences

LYELLyell Immunopharma2026-05-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

LYELLyell Immunopharma2026-04-07 12:00 EST

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

LYELLyell Immunopharma2026-03-12 20:05 EST

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Stock data

Close: 12.96 USD
Market cap: 347.44M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States